%PDF-1.4
%
44 0 obj
<>
endobj
41 0 obj
<>
endobj
113 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T18:28:52Z
2024-03-29T05:56:48-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T05:56:48-07:00
application/pdf
Heather
2002-657.suppl66
uuid:17eda819-1dd2-11b2-0a00-b409278d5b00
uuid:17eda81b-1dd2-11b2-0a00-1e0000000000
endstream
endobj
30 0 obj
<>
endobj
31 0 obj
<>
endobj
45 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
26 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
140 0 obj
[145 0 R]
endobj
141 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 714.5293 Tm
[(18.)-875 (Hamdy H, McKendry RJ, Mierins E, et al. Low-dose methotrexate)]TJ
0 Tc 2.175 -1.25 Td
(compared with azathioprine in the treatment of rheumatoid arthritis.)Tj
0 -1.25 TD
[(A)-220 (twenty-four)20 (-week controlled clinical trial. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1987;30:361-8.)Tj
0.02499 Tw -2.175 -1.25 Td
[(19.)-875 (Arnold MH, O\222Callaghan J, McCredie M, et al. Comparative)]TJ
2.175 -1.25 Td
(controlled trial of low-dose weekly methotrexate versus)Tj
T*
[(azathioprine in rheumatoid arthritis: 3-year prospective study)65 (. Br J)]TJ
T*
(Rheumatol 1990;29:120-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875 (Jeurissen MEC, Boerbooms )55 (AMT)74 (, van de Putte LBA, et al.)]TJ
0 Tc 2.175 -1.25 Td
(Methotrexate versus azathioprine in the treatment of rheumatoid)Tj
T*
[(arthritis: )55 (A)-220 (forty-eight-week randomized, double-blind trial.)]TJ
T*
(Arthritis Rheum 1991;34:961-72.)Tj
-2.175 -1.25 Td
[(21.)-875 (W)80 (einblatt ME, Kaplan H, Germain BF)80 (, et al. Low-dose)]TJ
2.175 -1.25 Td
(methotrexate compared with auranofin in adult rheumatoid arthritis.)Tj
T*
[(A)-220 (thirty-six week, double-blind trial. )55 (Arthritis Rheum 1990;)]TJ
0 Tw T*
(33:330-8.)Tj
0.02499 Tw -2.175 -1.25 Td
[(22.)-875 (Cohen S, Rutstein J, Luggen M, et al. Comparison of the safety and)]TJ
2.175 -1.25 Td
[(ef)18 (ficacy of cyclosporin )55 (A)-220 (and methotrexate in refractory rheumatoid)]TJ
T*
[(arthritis: )55 (A)-220 (randomized, multi-centered, placebo-controlled trial)]TJ
T*
[([abstract]. )55 (Arthritis Rheum 1993;36 Suppl:S56. )]TJ
30.825 23.75 Td
[(23.)-875 (Kremer JM, Phelps CT)74 (. Long-term prospective study of the use of)]TJ
2.175 -1.25 Td
(methotrexate in rheumatoid arthritis. Update after a mean of 90)Tj
T*
[(months. )55 (Arthritis Rheum 1992;35:138-45.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875 (W)80 (einblatt ME, )18 (W)80 (eissman BN, Holdsworth DE, et al. Long-term)]TJ
0 Tc 2.175 -1.25 Td
(prospective study of methotrexate in the treatment of rheumatoid)Tj
T*
[(arthritis. Eighty-four month update. )55 (Arthritis Rheum 1992;)]TJ
0 Tw T*
(35:129-37.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875 (Hanrahan PS, Scrivens GA, Russell )55 (AS. Prospective long-term)]TJ
0 Tc 2.175 -1.25 Td
[(follow-up of methotrexate therapy in rheumatoid arthritis: toxicity)65 (,)]TJ
T*
[(ef)18 (ficacy)65 (, and radiological progression. Br J Rheumatol)]TJ
0 Tw T*
(1989;28:147-53.)Tj
0.0249 Tw -2.175 -1.25 Td
[(26.)-875 (Reykdal S, Steinsson K, Sigurjonsson K, et al. Methotrexate )]TJ
2.175 -1.25 Td
[(treatment of rheumatoid arthritis: ef)18 (fects on radiological )]TJ
T*
(progression. Scand J Rheumatol 1989;18:221-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(27.)-875 (Felson DT)74 (, )55 (Anderson JJ, Meenan RF)80 (. Use of short-term)]TJ
0 Tc 2.175 -1.25 Td
[(ef)18 (ficacy/toxicity tradeof)18 (fs to select second-line drugs in rheumatoid)]TJ
T*
[(arthritis. )55 (A)-220 (metaanalysis of published clinical trials. )55 (Arthritis)]TJ
T*
[(Rheum 1992;35:1)37 (1)37 (17-25.)]TJ
/TT1 1 Tf
-35.4875 -63.5681 Td
(van de Putte: Results with single agents)Tj
0 Tw 61.9375 -0.0313 Td
(19)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 CS 0 0 0 1 SCN
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 cs 0 0 0 0 scn
104.62 57.5 407.5 -10.84 re
f*
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS1 CS 0 0 0 1 SCN
0.5 w
104.62 57.5 407.5 -10.84 re
S
Q
Q
q
1 0 0 1 0 -1 cm
0 0 612 792 re
W n
1 0 0 1 0 1 cm
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 50 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
96 0 obj
<>
endobj
119 0 obj
<>
endobj
53 0 obj
<>
endobj
48 0 obj
<>
endobj
50 0 obj
<>
endobj
61 0 obj
<>stream
HVpTιf!y^1op@